{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T15:58:27Z","timestamp":1648828707575},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00393-021-00984-7","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T23:02:20Z","timestamp":1615503740000},"page":"362-363","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Welche Therapieversuche sollten bei Einschlussk\u00f6rpermyositis unternommen werden?"],"prefix":"10.1007","volume":"80","author":[{"given":"Benedikt","family":"Schoser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"issue":"9","key":"984_CR1","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1093\/brain\/awz229","volume":"142","author":"O Benveniste","year":"2019","unstructured":"Benveniste\u00a0O, Allenbach\u00a0Y (2019) Inclusion body myositis: accumulation of evidence for its autoimmune origin. Brain 142(9):2549\u20132551","journal-title":"Brain"},{"key":"984_CR2","first-page":"712","volume":"548","author":"MC Dalakas","year":"1987","unstructured":"Dalakas\u00a0MC, Sonies\u00a0B, Dambrosia\u00a0J et al (1987) Treatment of inclusion body myositis with IVIG: a\u00a0double blind, placebo-conrolled study. Neurology 548:712\u2013716","journal-title":"Neurology"},{"key":"984_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"MC Walter","year":"2002","unstructured":"Walter\u00a0MC, Lochm\u00fcller\u00a0H, Toepfer\u00a0M et al (2002) High-dose immunoglobuline therapy (IVIG) in inclusion body myositis (IBM): A double-blind, placebo-controlled study. J\u00a0Neurol 247:22\u201328","journal-title":"J Neurol"},{"key":"984_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19886494","author":"S Glaubitz","year":"2020","unstructured":"Glaubitz\u00a0S, Zeng\u00a0R, Schmidt\u00a0J (2020) New insights into the treatment of myositis. Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1177\/1759720X19886494","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"984_CR5","unstructured":"https:\/\/dgn.org\/leitlinien\/ll-69-ll-myositissyndrome\/. Zugegriffen: 8. Febr. 2021"},{"issue":"9","key":"984_CR6","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","volume":"18","author":"MG Hanna","year":"2019","unstructured":"Hanna\u00a0MG, Badrising\u00a0UA, Benveniste\u00a0O et al (2019) Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a\u00a0randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol 18(9):834\u2013844","journal-title":"Lancet Neurol"},{"key":"984_CR7","doi-asserted-by":"publisher","first-page":"e1971","DOI":"10.1212\/WNL.0000000000010417","volume":"95","author":"K Sivakumar","year":"2020","unstructured":"Sivakumar\u00a0K, Cochrane\u00a0TI, Sloth\u00a0B et al (2020) Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis. Neurology 95:e1971\u2013e1978","journal-title":"Neurology"},{"key":"984_CR8","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00769860. Zugegriffen: 8. Febr. 2021"},{"issue":"suppl 10","key":"984_CR9","first-page":"40","volume":"69","author":"O Benveniste","year":"2019","unstructured":"Benveniste\u00a0O, Hogrel\u00a0JY, Annoussamy\u00a0M et\u00a0al (2019) Rapamycin vs.placebo for the treatment of inclusion body myositis: improvement of the 6\u202fmin walking distance, a\u00a0functional scale, the fvc and muscle quantitative MRI. Arthritis Rheumatol 69(suppl 10):40","journal-title":"Arthritis Rheumatol"},{"key":"984_CR10","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1016\/S2665-9913(20)30280-0","volume":"1","author":"O Benveniste","year":"2021","unstructured":"Benveniste\u00a0O, Hogrel\u00a0J\u2011Y, Belin\u00a0L et al (2021) Sirolimus for treatment of patients with inclusion body myositis: a\u00a0randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. Lancet Rheumatol 1:E40\u2013E48","journal-title":"Lancet Rheumatol"},{"key":"984_CR11","unstructured":"https:\/\/cureibm.org\/treatment\/introduction\/. Zugegriffen: 8. Febr. 2021"},{"key":"984_CR12","unstructured":"http:\/\/www.myositis-netz.de\/patienten-diagnosegruppe-myositis\/. Zugegriffen: 8. Febr. 2021"},{"key":"984_CR13","unstructured":"https:\/\/www.ibm-registry.org\/de\/. Zugegriffen: 8. Febr. 2021"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-00984-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-021-00984-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-00984-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T09:09:40Z","timestamp":1620119380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-021-00984-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1007\/s00393-021-00984-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]},"assertion":[{"value":"17 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0Schoser gibt an, Forschungsf\u00f6rderung durch das Bundesministerium f\u00fcr Bildung und Forschung, DGM, Sanofi Genzyme, Amicus, Greenovation erhalten zu haben. Honorar bzw. Kostenerstattung f\u00fcr Vortr\u00e4ge: Kedrion. Beratert\u00e4tigkeiten f\u00fcr: Amicus, Alexion, Audentes, Dyne, Lupin, Sanofi Genzyme, USB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}